{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-240127","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2022-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.952297+00:00","generated_at":"2026-06-23T14:24:48.745476+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Erasca reports 23% response rate in RAS/MAPK-altered non-CRC tumors; combo trial in H1 2023","bullets":["23% (6/26) of RAS/MAPK-altered non-CRC solid tumor patients responded to single-agent ERAS-007 or ERAS-601.","44% (4/9) of BRAF-driven non-CRC solid tumor patients responded (1 confirmed PR, 3 unconfirmed PRs).","Favorable safety profiles with largely non-overlapping, manageable treatment-related adverse events.","Company plans to initiate ERAS-007 + ERAS-601 (MAPKlamp) dose escalation trial in first half of 2023.","Retrospective pooled analysis included HERKULES-1, FLAGSHP-1, and ASN007-101 trials with data cutoffs through July 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-240127","json":"https://secwatch.observer/filing/0001193125-22-240127.json","markdown":"https://secwatch.observer/filing/0001193125-22-240127.md","text":"https://secwatch.observer/filing/0001193125-22-240127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000119312522240127/0001193125-22-240127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000119312522240127/d399259d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T14:24:48.745476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}